MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Erasca Inc

Cerrado

1.4 -4.11

Resumen

Variación precio

24h

Actual

Mínimo

1.4

Máximo

1.47

Métricas clave

By Trading Economics

Ingresos

1.3M

-31M

Empleados

103

EBITDA

-750K

-36M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+198.62% upside

Dividendos

By Dow Jones

Próximas Ganancias

8 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

8.5M

402M

Apertura anterior

5.51

Cierre anterior

1.4

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Erasca Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 jul 2025, 22:07 UTC

Principales Movimientos del Mercado

Trade Desk Rises on S&P 500 Inclusion

14 jul 2025, 17:06 UTC

Principales Movimientos del Mercado

Crypto Assets Rally Ahead of Possible U.S. Legislation

14 jul 2025, 16:47 UTC

Adquisiciones, fusiones, absorciones

NatWest to Sell Stake in Permanent TSB

14 jul 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

14 jul 2025, 23:38 UTC

Charlas de Mercado

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14 jul 2025, 23:37 UTC

Charlas de Mercado

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14 jul 2025, 23:29 UTC

Charlas de Mercado

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14 jul 2025, 23:29 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

14 jul 2025, 23:02 UTC

Ganancias

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14 jul 2025, 23:02 UTC

Ganancias

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14 jul 2025, 23:02 UTC

Ganancias

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14 jul 2025, 23:01 UTC

Ganancias

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14 jul 2025, 23:01 UTC

Ganancias

China Vanke Expects 1H Loss to Widen >000002.SZ

14 jul 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

14 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

14 jul 2025, 20:07 UTC

Charlas de Mercado

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14 jul 2025, 20:05 UTC

Charlas de Mercado

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14 jul 2025, 19:11 UTC

Charlas de Mercado

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14 jul 2025, 19:09 UTC

Charlas de Mercado

Gold Breaks a 3-Day Win Streak -- Market Talk

14 jul 2025, 18:59 UTC

Charlas de Mercado

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14 jul 2025, 18:30 UTC

Adquisiciones, fusiones, absorciones

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14 jul 2025, 18:25 UTC

Charlas de Mercado

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14 jul 2025, 18:25 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 jul 2025, 16:59 UTC

Charlas de Mercado

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14 jul 2025, 16:53 UTC

Acciones populares

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14 jul 2025, 16:27 UTC

Charlas de Mercado

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14 jul 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

14 jul 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

14 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

14 jul 2025, 16:12 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Comparación entre iguales

Cambio de precio

Erasca Inc previsión

Precio Objetivo

By TipRanks

198.62% repunte

Estimación a 12 Meses

Media 4.33 USD  198.62%

Máximo 6 USD

Mínimo 3 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.39 / 1.44Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Very Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.